{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[16,2,16,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910953431103321"]
[null,null,"Autore",null,"Källén Bengt"]
[null,null,"Titolo",null,"Drugs during pregnancy / / Bengt Källén"]
[null,null,"Pubbl/distr/stampa",null,"New York, : Nova Biomedical Books, c2009"]
[null,null,"ISBN",null,"1-61728-374-6"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (464 p.)"]
[null,null,"Collana",null,"Pregnancy and infants : medical, psychological and social issues series"]
[null,null,"Disciplina",null,"618.3/2"]
[null,null,"Soggetti",null,"Fetus - Effect of drugs on"]
[{"$nulls":4},"Pregnant women - Drug use"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Intro -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Abbreviations Used -- Chapter 1 -- A Short history of the study of maternal drug Use and delivery outcome -- The alert clinician -- Epidemiological studies -- References -- Chapter 2 -- The practical consequences of drug effects on delivery outcome -- 1. Introduction of a New drug into a market -- 2. A woman has Used the drug in early pregnancy -- 3. To prescribe a drug to a pregnant woman -- 4. A malformed infant was born and the mother remembers Having Taken a specific drug. -- A causal effect? -- Chapter 3 -- The Swedish health registers used  and variables studied -- The following records are included: -- MHV1 -- MHV2 -- FV1 -- FV2 -- The following data were used -- Year of delivery -- Maternal age -- Parity -- Smoking in early pregnancy -- Number of previous miscarriages -- Body Mass Index (BMI) -- Country of birth -- Family situation -- Work outside home -- Maternal education -- Maternal drug use -- Multiple births -- Maternal delivery diagnoses -- Delivery mode -- Pregnancy duration in completed weeks -- Infant sex -- Birth weight in gram -- Intrauterine growth -- Infant neonatal diagnoses -- Low Apgar score -- Congenital malformations in infants -- Any congenital malformation -- Chapter 4 -- Advantages and disadvantages of the study material -- Advantages -- Disadvantages -- Exposure information -- Outcome information -- Information on confounding factors -- References -- Chapter 5 -- Strategy of analysis -- Statistical notes -- References -- Chapter 6 -- Data on women and infants recorded in the Medical Birth Register during -- 1996-2005 -- Data on pregnancy outcome in all deliveries in the Medical Birth Register during 1996-2005 -- 1. Preterm birth, low "]
[{"$nulls":4},"birth weight, large birth weight, intrauterine growth -- 2. Infant sex and multiple births."]
[{"$nulls":4},"3. Maternal and infant diagnoses and infant outcome -- 4. Congenital malformations -- Chapter 7 -- Antacids -- Characteristics of women Using antacids -- Outcome after maternal Use of antacids -- Infant sex -- Multiple births -- Summary -- References -- Chapter 8 -- Drugs Used for gastric ulcer and gastro-oesophageal reflux -- Characteristics of women Using drugs for gastric ulcer or gastro-oesophageal reflux -- Outcome after maternal Use of drugs for stomach ulcer or gastro-oesophageal reflux -- Infant sex -- Multiple births -- Sucralfate -- Effects of concomitant drug use -- Summary -- References -- Chapter 9 -- Drugs Used for functional intestinal symptoms -- Characteristics of women Using drugs  for functional intestinal symptoms -- Outcome after maternal Use of drugs  for functional intestinal symptoms -- Infant sex -- Multiple births -- Summary -- References -- Chapter 10 -- Anti-Emetic drugs -- Outcome after maternal Use of antiemetic drugs -- Infant sex -- Multiple births -- Summary -- References -- Chapter 11 -- Bile acid preparations -- Outcome after maternal Use of Bile Acid preparations -- Infant sex -- Multiple birth -- Infant mortality -- Summary -- Chapter 12 -- Laxatives -- Characteristics of women Using laxatives -- Outcome after maternal Use of laxatives -- Infant sex -- Multiple births -- Summary -- References -- Chapter 13 -- Drugs Used as antidiarrhoics, intestinal anti-Infectives,  or at inflammatory bowel disease -- Characteristics for women Using drugs as antidiarrhoics, intestinal anti-infectives,  or at inflammatory bowel disease -- Outcome after maternal use of drugs Used as antidiarrhoics, intestinal anti-infectives,  or at inflammatory bowel disease -- Infant sex -- Multiple births -- Summary -- References -- Chapter 14 -- Anti-Obesity drugs -- Characteristics of women Using anti-Obesity drugs."]
[{"$nulls":4},"Outcome after maternal Use of anti-Obesity drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 15 -- Digestives, including enzymes -- Characteristics of women Using digestive drugs -- Outcome after maternal Use of digestive drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 16 -- Drugs for diabetes -- Characteristics of women Using antidiabetic drugs -- Outcome after maternal Use of antidiabetic drugs -- Infant sex -- Multiple births -- Summary -- References -- Chapter 17 -- Vitamins and minerals -- Characteristics of women Using vitamins  or minerals -- Outcome after maternal Use of vitamins  and minerals -- Infant sex -- Multiple births -- Summary -- References -- Chapter 18 -- Anabolic steroids -- Summary -- References -- Chapter 19 -- Anticoagulants -- Characteristics of women Using  anticoagulant drugs -- Outcome after maternal Use of anticoagulants -- Infant sex -- Multiple births -- Summary -- References -- Chapter 20 -- Haemostatics -- Characteristics of women Using Haemostatics -- Outcome after maternal Use of haemostatics -- Infant sex -- Multiple births -- Infant mortality -- K-vitamin -- Summary -- References -- Chapter 21 -- Vitamin B12 and folic acid -- Characteristics of women Using vitamin B12  or folic acid -- Outcome after maternal Use of vitamin B12  or folic acid -- Infant sex -- Multiple births -- Summary -- References -- Chapter 22 -- Drugs for cardiac diseases -- Characteristics of women Using drugs  for cardiac diseases -- Outcome after maternal Use of cardiac drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 23 -- Antihypertensives -- Characteristics of women Using drugs  for antihypertensives -- Outcome after maternal Use of antihypertensives -- Infant sex -- "]
[{"$nulls":4},"Multiple births -- Summary."]
[{"$nulls":4},"References -- Chapter 24 -- Diuretics -- Characteristics of women Using diuretics -- Outcome after maternal Use of diuretics -- Infant sex -- Multiple births -- Summary -- References -- Chapter 25 -- Serum lipid reducing agents -- Characteristics of women Using lipid  reducing drugs -- Outcome after maternal Use of lipid reducing drugs -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 26 -- Dermatological drugs -- Characteristics of women Using  dermatological drugs -- Outcome after maternal Use  of dermatological drugs -- Infant sex -- Multiple births -- Topical corticosteroids -- Other dermatological drugs -- Summary -- References -- Chapter 27 -- Gynaecological drugs -- Characteristics of women Using anti-infectives  or antiseptics vaginally -- Outcome after maternal Use of anti-infectives  or antiseptics vaginally -- Infant sex -- Multiple births -- Summary -- References -- Chapter 28 -- Prolactine inhibitors and dopamine agonists -- Characteristics of women Using prolactine inhibitors or dopamine agonists -- Outcome after maternal Use of prolactine inhibitors or dopamine agonists -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 29 -- Oral contraceptives -- Characteristics of women Using oral contraceptives in early pregnancy -- Outcome after maternal Use of oral contraceptives in early pregnancy -- Infant sex -- Multiple births -- Summary -- References -- Chapter 30 -- Sex hormones Other than oral contraceptives -- Characteristics of women Using progestogen drugs -- Outcome after maternal Use of progestogens -- Infant sex -- Multiple births -- Summary -- References -- Chapter 31 -- Ovulation stimulants -- Characteristics of women Using ovarian stimulants -- Outcome after maternal Use of ovarian stimulants -- Infant sex -- Multiple births -- Summary -- References."]
[{"$nulls":4},"Chapter 32 -- Urologicals -- Characteristics of women using urological drugs -- Outcome after maternal Use of urologics -- Infant sex -- Multiple births -- Summary -- Chapter 33 -- Hypophyseal and hypothalamic hormones (except gonadotrophines) and analogues -- Characteristics of women Using hypophyseal  or hypothalamic drugs -- Outcome after maternal Use of hypophyseal hormones other than gonadotrophines -- Infant sex -- Multiple births -- Summary -- References -- Chapter 34 -- Corticosteroids Used systemically -- Characteristics of women Using glucocorticoids -- Outcome after maternal Use  of glucocorticosteroids -- Infant sex -- Multiple births -- Summary -- References -- Chapter 35 -- Thyroid drugs -- Characteristics of women Using thyroid drugs -- Thyroid hormones -- Thyreostatics -- Outcome after maternal Use of thyroid drugs -- Infant sex -- Multiple births -- Summary -- References -- Chapter 36 -- Antibiotics Used systemically -- Characteristics of women Using antibiotics -- Outcome after maternal Use of antibiotics -- Infant sex -- Multiple births -- Trimethoprim -- Quinolone derivatives -- Summary -- References -- Chapter 37 -- Antimycotics Used systemically -- Characteristics of women Using systemic antimycotics -- Outcome after maternal Use of systemic antimycotics -- Infant sex -- Multiple births -- Infant mortality -- Summary -- References -- Chapter 38 -- Tuberculostatic drugs -- Characteristics of women Using  tuberculostatic drugs -- Outcome after maternal Use of  tuberculostatic drugs -- Infant sex -- Multiple births -- Infant mortality -- Pregnancy duration and infant birth weight at maternal use of tuberculostatic drugs -- Summary -- References -- Chapter 39 -- Anti-Virus drugs -- Characteristics of women Using antivirus drugs -- Outcome after maternal Use of antivirus drugs -- Infant sex -- Multiple births -- Summary -- References."]
[{"$nulls":4},"Chapter 40."]
[null,null,null,"Sommario/riassunto","This book discusses the problems in studying the effect of maternal drug use during pregnancy and delivery outcome, including congenital malformations and other defects of the infants. For each main category of relevant drugs, information gathered from the literature and data obtained from the Swedish Medical Birth Register are used. This register is a rather unique source of information because during the time interval studies, nearly one million women have been interviewed in early pregnancy about the use of drugs during pregnancy and data from their deliveries and their infants have been collected. This book will contribute to the scientific literature because of much of the data have never been published as scientific articles and previously published data will be updated"]